Research Article
Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Table 3
Univariate and multivariate analysis of OS in the enrolled cohort.
| Variable | No. of cases | Univariate analysis | Multivariate analysis | HR (95% CI) | value | HR (95% CI) | value |
| Gender (male versus female) | 67/15 | 0.53 (0.29–0.96) | 0.036 | | | Age (≤50 versus >50) | 25/57 | 0.89 (0.52–1.53) | 0.669 | | | Tumor size (cm) (≤5/>5–≤10/>10) | 37/31/14 | | 0.852 | | | ≤5 versus >10 | 37/14 | 1.00 (0.51–1.96) | 0.991 | | | >5–≤10 versus >10 | 31/14 | 0.87 (0.43–1.74) | 0.688 | | | AJCC TNM stage (III versus IV) | 47/35 | 1.00 (0.62–1.61) | 0.986 | | | ECOG (≤1 versus >1) | 72/10 | 1.44 (0.68–3.04) | 0.338 | | | Etiology (HBV/HCV/none HBV, none HCV) | 66/6/10 | | 0.849 | | | HBV versus none HBV, none HCV | 66/10 | 0.83 (0.41–1.68) | 0.597 | | | HCV versus none HBV, none HCV | 6/10 | 0.76 (0.23–2.48) | 0.647 | | | Antiviral therapy (yes versus no) | 43/39 | 1.47 (0.89–2.42) | 0.131 | | | Child–Pugh classification (A versus B) | 79/3 | 0.14 (0.03–0.67) | 0.014 | 0.12 (0.03–0.60) | 0.010 | ALT levels, IU/L (≤40/>40–≤100/>100) | 69/11/2 | | 0.152 | | | ≤40 versus >100 | 69/2 | 0.89 (0.12–6.49) | 0.909 | | | > 40–≤100 versus >100 | 11/2 | 1.75 (0.22–13.82) | 0.594 | | | AFP levels (μg/L) (≤20/20–400/≥400) | 22/19/41 | | 0.035 | | | ≤20 versus ≥400 | 22/41 | 1.95 (1.10–3.47) | 0.022 | | | 20–400 versus ≥400 | 19/41 | 0.89 (0.47–1.66) | 0.704 | | | PVTT typing (II/III/IV) | 22/44/13 | | 0.878 | | | II versus IV | 22/13 | 1.09 (0.53–2.27) | 0.811 | | | III versus IV | 44/13 | 1.18 (0.61–2.28) | 0.622 | | | Radiation dose (Gy) (≤50 versus >50) | 51/31 | 1.69 (1.02–2.81) | 0.042 | | | Overall response (response versus no response) | 43/39 | 0.41 (0.25–0.69) | 0.001 | 0.41 (0.24–0.68) | 0.001 | AFP response (≥20% versus <20%) | 35/47 | 0.55 (0.33–0.91) | 0.019 | 0.51 (0.30–0.84) | 0.009 | Sorafenib (yes versus no) | 36/46 | 0.55 (0.33–0.90) | 0.018 | | |
|
|